| Literature DB >> 31788965 |
Hao-Yang Wang1, Rui Zhang Md1,2, Ze-Yu Luo1, Duan Wang Md PhD1, Fu-Xing Pei1, Xin Tang1, Zong-Ke Zhou1.
Abstract
OBJECTIVE: To assess the safety and effectiveness of one-stage total joint arthroplasty (TJA) or revision for seronegative infections after total hip arthroplasty (THA) and total knee arthroplasty (TKA).Entities:
Keywords: Arthroplasty; One-stage revision; Seronegative infection
Year: 2019 PMID: 31788965 PMCID: PMC7031574 DOI: 10.1111/os.12545
Source DB: PubMed Journal: Orthop Surg ISSN: 1757-7853 Impact factor: 2.071
Main characteristics of the patients included in the study
| Variables | Patients ( |
|---|---|
| Age, mean ± SD | 56.9 ± 11.5 |
| Gender (number [%] of patients) | |
| Male | 312 (63.03) |
| Female | 183 (36.97) |
| Height (cm), mean ± SD | 163.14 ± 5.63 |
| Weight (kg), mean ± SD | 63.78 ± 3.31 |
| BMI, mean ± SD | 24.3 ± 3.2 |
| Diagnosis (number [%] of patients) of patients undertaking one‐stage total joint arthroplasty or revision | |
| Hip osteoarthritis secondary to sepsis | 94 (19) |
| Hip osteoarthritis or ONFH secondary to trauma | 40 (8) |
| Prothesis loosening after THA | 302 (61) |
| Knee osteoarthritis secondary to sepsis | 0 (0) |
| Knee osteoarthritis secondary to trauma | 10 (2) |
| Prothesis loosening after TKA | 49 (10) |
| Concealed infection (number [%] of patients) | |
| Hip osteoarthritis secondary to sepsis | 2 (2.12) |
| Hip osteoarthritis or ONFH secondary to trauma | 4 (10.00) |
| Prothesis loosening after THA | 14 (4.64) |
| Knee osteoarthritis secondary to sepsis | 0 (0) |
| Knee osteoarthritis secondary to trauma | 0 (0) |
| Prothesis loosening after TKA | 4 (8.16) |
| Time of surgery(min), mean ± SD | 81 ± 19.2 |
| Follow‐up(month), mean ± SD | 35.67 ± 4.71 |
BMI, body mass index; ONFH, osteonecrosis of femoral head; THA, total hip arthroplasty; TKA, total knee arthroplasty.
Figure 1A 64‐year‐old woman, with one‐stage revision of the right knee for prothesis loosening. Bacterial culture of synovial fluid shows the Staphylococcus epidermidis infection. (A) 3 years after the primary TKA. (B) 1 day after the revision. (C) 39 months after the revision, no radiolucent lines were found, and no migration, osteolysis, or subsidence were detected. The components were considered to be stable.
Figure 2A 48‐year‐old man, with one‐stage revision of the right hip for prothesis loosening and primary THA of the left hip; bacterial culture of synovial fluid from the right hip shows the Staphylococcus capitis infection. (A) 8 years after the primary THA. (B) 1 day after the revision of the right hip and the primary THA of the left hip. (C) 35 months after the revision, no radiolucent lines were found. No migration, osteolysis, or subsidence were detected. The components were considered to be stable.
Figure 3A 42‐year‐old woman underwent one‐stage arthroplasty of the right hip for failure of the femoral neck fracture at the right side. Bacterial culture of synovial fluid from the right hip shows the Staphylococcus epidermidis infection. (A) 2 years after the internal fixation of the femoral neck. (B) 1 day after primary THA of the right hip. (C) 29 months after primary THA of the right hip. No radiolucent lines were found. No migration, osteolysis, or subsidence were detected. The components were considered to be stable.
Main characteristics of studies of one‐stage versus two‐stage revision and one‐stage only
| Authors Year of study | Type of surgery | Duration of antibiotics use | Rate of infection control | Mean follow‐up |
|---|---|---|---|---|
| Knee | ||||
| One‐stage revision versus two‐stage revision | ||||
| Lecuire and Collodel | One‐stage | Intravenous | One‐stage | 79.2 months |
| ( | 21 days | 93.80% | ||
| Two‐stage | Oral | Two‐stage | ||
| ( | 6 months | 97.60% | ||
| Oussedik and Dodd | One‐stage | Intravenous | One‐stage | 81.6 months |
| ( | 5 days | 100.00% | ||
| Two‐stage | Oral | Two‐stage | ||
| ( | 6 weeks | 94.90% | ||
| Klouche and Leonard | One‐stage | Intravenous | One‐stage | 24 months |
| ( | 6 weeks | 100.00% | ||
| Two‐stage | Oral | Two‐stage | ||
| ( | 6 weeks | 97.80% | ||
| Choi and Kwon | One‐stage | Intravenous | One‐stage | 61 months |
| ( | 6 weeks | 82.00% | ||
| Two‐stage | Oral | Two‐stage | ||
| ( | — | 71.50% | ||
| Wolf and Clar | One‐stage | 6 weeks in total or 2 weeks after drug sensitivity test | One‐stage | 24 months |
| ( | 56.80% | |||
| Two‐stage | Two‐stage | |||
| ( | 94.50% | |||
| Li and Hou | One‐stage | Intravenous and oral | One‐stage | 103.2 months |
| ( | for 6–12 weeks | 100.00% | ||
| Two‐stage | Two‐stage | |||
| ( | 100.00% | |||
| One‐stage revision | ||||
| Wroblewski | One‐stage | Intravenous | One‐stage | 38 months |
| ( | 2 days | 91.00% | ||
| Oral | ||||
| 6 weeks | ||||
| Raut and Siney | One‐stage | Intravenous | One‐stage | 88 months |
| ( | from operation to sensitivity results | 86.00% | ||
| Oral | ||||
| 6 weeks to 3 months | ||||
| Raut and Siney | One‐stage | Intravenous | One‐stage | 93 months |
| ( | 4 weeks (2 patients) | 84.20% | ||
| Oral | ||||
| 6 weeks to 3 months (146 patients) | ||||
| Rudelli and Uip | One‐stage | Intravenous | One‐stage | 103 months |
| ( | at least 4 weeks | 93.80% | ||
| Oral | ||||
| maintained to 6 months postoperation | ||||
| Yoo and Kwon | One‐stage | Intravenous | One‐stage | 86.4 months |
| ( | 4.9 weeks for all | 91.67% | ||
| Oral | ||||
| 6 weeks for 7 of 12 | ||||
| Singer and Merz | One‐stage | Intravenous | One‐stage | 36 months |
| ( | 2 weeks | 95.00% | ||
| Oral | ||||
| 4 weeks | ||||
|
Bori and Mahamud | One‐stage | Intravenous | One‐stage | 44.6 months |
| ( | 10 days | 95.80% | ||
| Oral | ||||
| 50.1 days | ||||
|
Zeller and Lhotellier | One‐stage | Intravenous | One‐stage | 41.6 months |
| ( | 4 to 6 weeks | 94.90% | ||
| Oral | ||||
| 6 to 8 weeks | ||||
| Knee | ||||
| One‐stage revision versus two‐stage revision | ||||
|
Scott and Stockley | One‐stage | Not concern | One‐stage | Not concern |
| ( | 70.00% | |||
| Two‐stage | Two‐stage | |||
| ( | 100.00% | |||
|
Buechel and Femino | One‐stage | Intravenous | One‐stage | 122.4 months |
| ( | 4–6 weeks | 90.90% | ||
| Oral | ||||
| 6–12 months | ||||
|
Laffer and Graber | One‐stage | 67.6% use for more than 6 months, 32.3% use less than 6 months | One‐stage | 28 months |
| ( | 100.00% | |||
| Two‐stage | Two‐stage | |||
| ( | 84.60% | |||
|
Prasad and Paringe | One‐stage | Intravenous | One‐stage | 60 months |
| ( | 5 days | 88.00% | ||
| Two‐stage | Oral | Two‐stage | ||
| ( | 6 weeks | 94.00% | ||
|
Haddad and Sukeik |
One‐stage ( | 1 to 6 weeks intravenous |
One‐stage 100.00% | 78 months |
|
Two‐stage ( | 5 days intravenous continue for 6 weeks Intravenous or oral |
Two‐stage 93.00% | ||
|
Massin and Delory | One‐stage | total 6 weeks | One‐stage | One‐stage |
| ( | 79.00% | 44 months | ||
| Two‐stage | Two‐stage | Two‐stage | ||
| ( | 69.00% | 55 months | ||
| One‐stage revision | ||||
|
Singer and Merz | One‐stage | Intravenous | One‐stage | 36 months |
| ( | 2 weeks | 95.00% | ||
| Oral | ||||
| 4 weeks | ||||
|
Tibrewal and Malagelada | One‐stage | Intravenous | One‐stage | 126 months |
| ( | 2 weeks | 98.00% | ||
| Oral | ||||
| 3 months | ||||
|
Labruyere and Zeller | One‐stage | Intravenous | One‐stage | 60 months |
| ( | 6 weeks | 100.00% | ||
| Oral | ||||
| 6 weeks | ||||
|
Zahar and Kendoff | One‐stage | Intravenous | One‐stage | 120 months |
| ( | 14.2 days | 93.00% | ||
| Oral | ||||
| none | ||||
The information of laboratory examination and clinical outcomes before and after operation
| Number | Surgery | ESR | CRP | WBC | Time for drug sensitivity (Days) | Culture | Number of antibiotics | Multiple resistant bacteria | Antibiotics | Harri hip score | Harri hip score | PCS | PCS | Follow up (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| site | (mm/h) | (mg/L) | (109/L) | Introp. | Sensitive | IV | Or | Or | MCS | MCS | ||||
| NEUT | 1 week | Insensitivity | Oral | HSS score | HSS score | Preop. | Postop. | |||||||
| (%) | 2 weeks | Preop. | Postop. | |||||||||||
| Finish drug use | ||||||||||||||
| 1 | Hip | 19 | 5.66 | 6.14 | 3 |
| 17 | No | Va + Ce | 36 | 90 | 9 | 20 | 40 |
| 56.3 | No | 0 | Ri | 14 | 23 | |||||||||
| No | ||||||||||||||
| 2 | Hip | 30 | 7.19 | 7.45 | 3 |
| 19 | No | Va + Ce | 32 | 89 | 11 | 19 | 36 |
| 66.1 | No | 0 | Ri | 13 | 22 | |||||||||
| No | ||||||||||||||
| 3 | Hip | 17 | 4.06 | 7.02 | 3 |
| 21 | Yes | Ce + Su | 34 | 87 | 11 | 19 | 39 |
| 74.3 | Yes | 6 | Ri | 15 | 26 | |||||||||
| No | ||||||||||||||
| 4 | Hip | 12 | 6.51 | 8.13 | 3 |
| 12 | No | Va + Le | 32 | 92 | 8 | 18 | 38 |
| 58.4 | No | 0 | Ri | 13 | 25 | |||||||||
| No | ||||||||||||||
| 5 | Hip | 16 | 2.31 | 6.42 | 2 |
| 14 | No | Va + Le | 28 | 90 | 9 | 22 | 34 |
| 58.4 | No | 2 | Ri | 10 | 20 | |||||||||
| No | ||||||||||||||
| 6 | Hip | 31 | 3.35 | 3.23 | 3 |
| 16 | No | Va + Ce | 21 | 85 | 10 | 22 | 29 |
| 65.2 | No | 4 | Ri | 11 | 22 | |||||||||
| No | ||||||||||||||
| 7 | Hip | 27 | 5.3 | 8.21 | 4 |
| 10 | No | Ce + Le | 36 | 84 | 10 | 20 | 36 |
| 59.5 | No | 2 | Le | 11 | 22 | |||||||||
| No | ||||||||||||||
| 8 | Hip | 44 | 6.85 | 5.25 | 3 |
| 12 | No | Va + Ce | 24 | 89 | 7 | 17 | 29 |
| 56.9 | No | 2 | Ri | 13 | 24 | |||||||||
| No | ||||||||||||||
| 9 | Hip | 63 | 6.3 | 7.1 | 3 |
| 14 | No | Ce + Su | 31 | 92 | 7 | 19 | 36 |
| 59.4 | No | 2 | Ri | 14 | 29 | |||||||||
| No | ||||||||||||||
| 10 | Hip | 24 | 3.83 | 5.53 | 4 |
| 15 | No | Le | 30 | 96 | 14 | 24 | 35 |
| 67.8 | No | 2 | Le | 16 | 24 | |||||||||
| No | ||||||||||||||
| 11 | Hip | 38 | 6.27 | 6.6 | 2 |
| 10 | No | Va + Ce | 29 | 91 | 6 | 20 | 35 |
| 59.2 | No | 0 | Ri | 13 | 25 | |||||||||
| No | ||||||||||||||
| 12 | Hip | 11 | 1 | 5.7 | 4 | Klebsiella oxytoca | 23 | No | Le + Ce + Su | 10 | 89 | 9 | 22 | 29 |
| 56.7 | No | 5 | 12 | 27 | ||||||||||
| No | ||||||||||||||
| 13 | Hip | 21 | 1 | 4.22 | 2 |
| 13 | No | Va + Le | 44 | 77 | 10 | 21 | 29 |
| 46.6 | No | 0 | Ri | 12 | 28 | |||||||||
| No | ||||||||||||||
| 14 | Hip | 18 | 4.32 | 5.32 | 4 | Klebsiella oxytoca | 16 | No | Le + Ce + Su | 32 | 79 | 15 | 19 | 30 |
| 48.9 | No | 2 | Le | 15 | 27 | |||||||||
| No | ||||||||||||||
| 15 | Hip | 17 | 5.12 | 6.39 | 3 |
| 11 | No | Va + Ce | 56 | 82 | 9 | 23 | 38 |
| 55.2 | No | 2 | Ri | 14 | 27 | |||||||||
| No | ||||||||||||||
| 16 | Hip | 26 | 6.01 | 6.67 | 3 | Staphylococcus saprophyticus | 16 | No | Va | 34 | 87 | 13 | 24 | 37 |
| 52.4 | Yes | 3 | Ri | 13 | 26 | |||||||||
| No | ||||||||||||||
| 17 | Hip | 14 | 2.23 | 7.01 | 3 |
| 11 | No | Va + Le | 47 | 69 | 11 | 15 | 49 |
| 68.5 | No | 2 | Ri | 13 | 23 | |||||||||
| No | ||||||||||||||
| 18 | Hip | 31 | 4.87 | 8.13 | 2 |
| 13 | No | Va | 41 | 76 | 12 | 18 | 40 |
| 62.5 | No | 2 | Ri | 13 | 21 | |||||||||
| No | ||||||||||||||
| 19 | Hip | 22 | 6.65 | 7.49 | 3 |
| 13 | No | Va | 39 | 79 | 11 | 19 | 44 |
| 49.8 | No | 2 | Ri | 16 | 20 | |||||||||
| No | ||||||||||||||
| 20 | Hip | 16 | 1.05 | 4.66 | 3 | Staphylococcus saprophyticus | 8 | No | Va + Le | 38 | 82 | 9 | 21 | 50 |
| 50.2 | No | 2 | Ri | 17 | 29 | |||||||||
| No | ||||||||||||||
| 21 | Knee | 14 | 7.3 | 8.75 | 2 |
| 15 | No | Va | 48 | 74 | 13 | 23 | 39 |
| 63.12 | No | 2 | Ri | 11 | 22 | |||||||||
| No | ||||||||||||||
| 22 | Knee | 15 | 7.85 | 8.82 | 4 | Candida | 5 | No | Fl | 51 | 85 | 9 | 24 | 38 |
| 65.4 | No | 1 | Fl | 12 | 21 | |||||||||
| No | ||||||||||||||
| 23 | Knee | 32 | 6.48 | 8.93 | 4 |
| 15 | No | Va + Ce | 50 | 88 | 10 | 20 | 28 |
| 66.9 | No | 2 | Ri | 14 | 28 | |||||||||
| No | ||||||||||||||
| 24 | Knee | 29 | 7.98 | 8.52 | 3 |
| 19 | Yes | Va + Le | 48 | 69 | 11 | 17 | 27 |
| 70.1 | No | 5 | Ri | 10 | 21 | |||||||||
| No |
ESR, erythrocyte sedimentation rate; CRP, c‐reactive protein; WBC, white blood cell; NEUT, neutrophil count.